RxDoctor Payments Data

John Ferrante, MD

Internal Medicine · Milton, MANPI 1649269523

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 64 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$275
  • Avion Pharmaceuticals$177
  • AstraZeneca$173
  • Exact Sciences$143
  • Tolmar, Inc.$90
  • E.r. Squibb & Sons, L.L.C.$89
  • plus $395 from 13 others

What the payments were for

  • Food & beverage$1,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,342 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$70,988
Medicare patients
264
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$99,040
JardianceEmpagliflozin18$17,127
FarxigaDapagliflozin Propanediol12$8,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,749
Tegretol XrCarbamazepine29$6,696
Metoprolol Succinate288$5,421
Atorvastatin Calcium281$4,125
Epinephrine14$4,014
Sildenafil Citrate21$3,875
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,523
Omeprazole219$3,192
Pravastatin Sodium132$2,521
Gabapentin189$2,322
Carbamazepine ErCarbamazepine14$2,175
Albuterol Sulfate HfaAlbuterol Sulfate84$2,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$275$99,040133 claims
AstraZenecaFarxiga$173$8,81712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Milton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →